Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis-Reference-Cited by-同舟云学术

Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Published:2019-11-02 Issue:2 Volume:71 Page:415-418
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Seung Kwonjune J¹,Khan Palwasha²,Franke Molly F³,Ahmed Saman²,Aiylchiev Stalbek⁴,Alam Manzur⁵,Putri Fauziah Asnely⁶,Bastard Mathieu⁷,Docteur Wisny⁸,Gottlieb Gary¹,Hewison Catherine⁹,Islam Shirajul⁵,Khachatryan Naira¹⁰,Kotrikadze Tinatin¹¹,Khan Uzma¹²,Kumsa Andargachew¹³,Lecca Leonid¹⁴,Tassew Yoseph Melaku¹⁵,Melikyan Nara¹⁵,Naing Ye Yint¹⁶,Oyewusi Lawrence¹⁷,Rich Michael¹,Wanjala Stephen¹⁸,Yedilbayev Askar¹,Huerga Helena⁷,Mitnick Carole D³

Affiliation:

1. Partners In Health, Boston, Massachusetts, USA

2. Interactive Research and Development, Karachi, Pakistan

3. Department of Global Health and Social Medicine, Harvard Medical School and Partners In Health, Boston, Massachusetts, USA

4. Médecins Sans Frontières, Kyrgyzstan

5. Interactive Research and Development, Dhaka, Bangladesh

6. Interactive Research and Development, Indonesia

7. Field Epidemiology Department, Epicentre, Paris, France

8. Zanmi Lasante, Port-Au-Prince, Haiti

9. Medical Department, Médecins Sans Frontières, Paris, France

10. Médecins Sans Frontières, Armenia

11. Médecins Sans Frontières, Georgia

12. Interactive Research and Development, Dubai, United Arab Emirates

13. Partners In Health, Addis Ababa, Ethiopia

14. Socios En Salud, Lima, Peru

15. Médecins Sans Frontières, Belarus

16. Médecins Sans Frontières, Myanmar

17. Partners In Health, Maseru, Lesotho

18. Médecins Sans Frontières, Kenya

Abstract

Abstract Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.

Funder

Unitaid

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciz1084/30341941/ciz1084.pdf

Reference14 articles.

1. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group Phase 3 trial;von Groote-Bidlingmaier;Lancet Respir Med,2019

2. Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong;Chang;Eur Respir J,2018

3. Six-month response to delamanid treatment in MDR TB patients;Hewison;Emerg Infect Dis,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid;Scientific Reports;2024-07-29

2. Efficacy and safety of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in adults: A systematic review and meta-analysis;Indian Journal of Tuberculosis;2024-01

3. Atosiban and Rutin exhibit anti-mycobacterial activity - An integrated computational and biophysical insight toward drug repurposing strategy against Mycobacterium tuberculosis targeting its essential enzyme HemD;International Journal of Biological Macromolecules;2023-12

4. Effectiveness and safety of regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis;Perspectives in Clinical Research;2023-09-11

5. Factors Associated with Unsuccessful Treatment of Bedaquiline and or Delamanid Based Regimens in Multidrug-Resistant Tuberculosis: A Review;Journal of Pharmaceutical and Sciences;2023-06-12